

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.

PW MEDTECH GROUP LIMITED

普华和顺集团公司

(Incorporated in the Cayman Islands with limited liability)

(Stock Code: 1358)

OVERSEAS REGULATORY ANNOUNCEMENT RESULTS OF A SUBSIDIARY

This announcement is made pursuant to Rule 13.10B of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited.

Sichuan Rekind Medtec., Inc. (also known as Sichuan Ruijian Medical Technology Co. Ltd.) (四川睿健醫療科技股份有限公司) (NEEQ stock code: 874652) (“**Sichuan Ruijian Medical**”), a non-wholly owned subsidiary of PW Medtech Group Limited (the “**Company**”, together with its subsidiaries, the “**Group**”), has announced its financial estimates (業績預告) for the first quarter of 2025 on the designated disclosure platform of the National Equities Exchange and Quotation System (“**NEEQS**”) (www.neeq.com.cn). The financial statements of Sichuan Ruijian Medical have been prepared in conformity with China Accounting Standards for Business Enterprises.

A summary of the financial estimates of Sichuan Ruijian Medical for the first quarter of 2025 is provided below.

Unit: RMB ten thousand

Item	First quarter of 2025 (January – March) (Estimates)	First quarter of 2024 (January – March)	Period-over-Period change
Revenue	12,000.00–15,000.00	10,045.90	19.45% – 49.31%
Net profit attributable to the shareholders of Sichuan Ruijian Medical	2,600.00–3,200.00	3,256.22	-20.15% – -1.73% ⁽¹⁾
Net profit attributable to the shareholders of Sichuan Ruijian Medical after deducting non-recurring gain or loss items	2,600.00–3,200.00	3,163.09	-17.80% – 1.17%

Note:

- (1) The decrease in the net profit attributable to the shareholders of Sichuan Ruijian Medical for the first quarter of 2025 as compared to the same period of 2024 was mainly due to the implementation of stock incentive plan for employees by Sichuan Ruijian Medical in April 2024, and the recognition of share-based payments in the first quarter of 2025, which resulted in a decrease in net profit compared to the same period of 2024.

GENERAL INFORMATION

The Company is an exempted company incorporated under the laws of the Cayman Islands with limited liability on May 13, 2011. The principal business activity of the Company is investment holding. The Group is principally engaged in the research and development (“**R&D**”), manufacturing and sales of (i) advanced infusion set, intravenous cannula products, insulin needles etc., (ii) blood purification medical devices, and (iii) animal-derived regenerative medical biomaterial and human tissue repair alternative products in the People’s Republic of China (the “**PRC**”).

Sichuan Ruijian Medical is a joint stock limited liability company established in the PRC on August 6, 2013, the shares of which are quoted on the NEEQS (NEEQ stock code: 874652). Sichuan Ruijian Medical is a medical device company, principally engaged in the R&D, manufacturing and sales of medical device for blood purification.

Shareholders of the Company should note that the above financial estimates for the first quarter of 2025 pertain only to Sichuan Ruijian Medical, and are Sichuan Ruijian Medical’s preliminary estimates which has not been audited or reviewed by auditors and do not constitute a profit forecast or performance commitment. Public investors and shareholders of the Company should exercise caution when dealing in its securities.

By order of the Board
PW Medtech Group Limited
Yue’e Zhang
Chairman & Chief Executive Officer

Hong Kong, March 27, 2025

As at the date of this announcement, the Board comprises one executive Director, namely, Ms. Yue’e Zhang; two non-executive Directors, namely, Mr. Jiang Liwei and Mr. Lin Junshan; and three independent non-executive Directors, namely, Mr. Wang Xiaogang, Mr. Chen Geng and Ms. Wang Fengli.